DDInter1938 DDInter1435
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vincristine {u} (Compound) resembles {v} (Compound) Voacamine
Vincristine {u} (Compound) treats {v} (Disease) muscle cancer
Vincristine {u} (Compound) binds {v} (Gene) TUBB
Vincristine {u} (Compound) upregulates {v} (Gene) TICAM1
Vincristine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vincristine {u} (Compound) downregulates {v} (Gene) BRCA1
Vincristine {u} (Compound) causes {v} (Side Effect) Respiratory distress
Vincristine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) TUBB2A
Vincristine (Compound) resembles Vinorelbine (Compound)
Vincristine (Compound) resembles Voacamine (Compound)
Vincristine (Compound) treats muscle cancer (Disease)
Vincristine (Compound) binds TUBB (Gene)
Vincristine (Compound) upregulates TICAM1 (Gene)
Vincristine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vincristine (Compound) downregulates BRCA1 (Gene)
Vincristine (Compound) causes Respiratory distress (Side Effect)
Vincristine (Compound) binds TUBB2A (Gene) and Vincristine (Compound) upregulates TUBB2A (Gene)